GlassScriptPhysician profile
John Kenyon Larsen
NPI 1538422118
$49,301.99
in general payments reported to CMS, 2019-2025
42 companies · $38K in 2025
The $38K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,000 · 2022: $2,298 · 2023: $2,881 · 2024: $4,543 · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Consulting Fee: $12K · Food and Beverage: $8,404 · Travel and Lodging: $6,152 · Education: $67.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,397.87 |
| Consulting Fee | $11,983.00 |
| Food and Beverage | $8,404.07 |
| Travel and Lodging | $6,151.70 |
| Education | $67.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $31,214.17 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $5,309.46 | 2021-2025 | Fasenra, Breztri, Airsupra |
| Genzyme Corporation | $3,713.56 | 2021-2025 | |
| Glaxosmithkline, LLC. | $3,051.35 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Pharmaceuticals, INC. | $1,344.00 | 2025 | Dupixent |
| Abbvie INC. | $597.05 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $400.00 | 2024-2025 | |
| Mylan Specialty L.P. | $310.98 | 2021-2023 | Yupelri |
| Grifols USA, LLC | $288.45 | 2021-2022 | |
| Baxter Healthcare | $264.46 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.66 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $239.42 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $215.06 | 2023-2025 | Uptravi, Opsumit |
| Verona Pharma, INC. | $208.67 | 2025 | Ohtuvayre |
| Biogen, INC. | $181.09 | 2021-2023 | Vumerity, Tysabri, Tysabri |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $155.46 | 2021 | |
| Emd Serono, INC. | $154.64 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $147.04 | 2022-2023 | Ongentys, Ingrezza |
| Lilly USA, LLC | $136.05 | 2023-2025 | Zepbound, Amyvid |
| Advanced Respiratory, INC | $133.29 | 2021 | |
| Celgene Corporation | $131.11 | 2021-2022 | |
| Amgen INC. | $125.09 | 2021-2023 | Aimovig |
| Alexion Pharmaceuticals, INC. | $103.37 | 2021-2023 | Ultomiris |
| Lundbeck LLC | $88.37 | 2021-2023 | Vyepti |
| Mannkind Corporation | $77.91 | 2023 | Afrezza |
| Pfizer INC. | $66.88 | 2023 | |
| Merck Sharp & Dohme LLC | $43.03 | 2024-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Acorda Therapeutics, INC | $39.01 | 2023 | Inbrija |
| Janssen Pharmaceuticals, INC | $37.88 | 2021 | |
| Upsher-Smith Laboratories LLC | $35.81 | 2023 | |
| Argenx US, INC. | $32.06 | 2023 | Vyvgart |
| Cala Health, INC. | $25.86 | 2023 | Cala Kiq, Cala Trio |
| Genentech USA, INC. | $25.46 | 2023 | Ocrevus, Enspryng, Xolair |
| Exact Sciences Corporation | $22.03 | 2025 | Cologuard Collection Kit |
| Insmed, INC. | $20.21 | 2025 | Arikayce |
| Viatris Specialty LLC | $18.91 | 2025 | Yupelri |
| Alnylam Pharmaceuticals INC. | $18.45 | 2021 | |
| Banner Life Sciences, LLC | $17.99 | 2023 | |
| Daiichi Sankyo INC. | $17.74 | 2025 | Injectafer |
| Ucb, INC. | $17.35 | 2023 | Fintepla |
| Novartis Pharmaceuticals Corporation | $15.53 | 2021 | |
| Impel Pharmaceuticals INC. | $14.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Larsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.